Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
HNF4A	3172	LINOLEIC ACID	CHEMBL267476	agonist	GuideToPharmacologyInteractions
HNF4A	3172	ROSIGLITAZONE	CHEMBL121		NCI	15998575
HNF4A	3172	MYRISTIC ACID	CHEMBL111077		DrugBank	10592235
HNF4A	3172	DODECANOATE	CHEMBL108766		DrugBank	10592235
HNF4A	3172	UREA	CHEMBL985		NCI	8167573
HNF4A	3172	CETUXIMAB	CHEMBL1201577		NCI	8777337
HNF4A	3172	ANDROSTENEDIONE	CHEMBL274826		NCI	9260906
HNF4A	3172	TESTOSTERONE	CHEMBL386630		NCI	9260906
HNF4A	3172	ALBUMIN HUMAN	CHEMBL1201451		NCI	8788167

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
HNF4A	rs2071197	AA	lamotrigine	metabolism/PK	yes	The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance.	Genotype AA is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.	26213157	1448098929
HNF4A	rs3212198	T	warfarin	dosage	yes	Please note this association is found for a combination of two variants. Patients with rs2501873 (TT) and at least one variant allele in HNF4a rs3212198 (T allele) required higher warfarin doses (6.2±2.4mg) than those with other combinations (5.3± 1.7mg, ranging from 5.2 ±1.9 to 5.5± 1.9mg). These variant combination explained 1.7% of the overall interindividual variability in warfarin dose requirements among the study patients in a multivariate regression analysis (p=0.019).	Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	25356900	1184997918
HNF4A	rs3212183	C	lamotrigine	efficacy	no	Efficacy was determined by monitoring the frequency of patients' epileptic seizures within one year. Each patient was evaluated at 4 weeks after treatment initiation and then at 3-month intervals thereafter. The difference in seizure frequency was based on the difference between the 3-month retrospective baseline frequency and the seizure frequency at 12-month visit, which was reported for the last 3 months prior to the last visit. Good efficacy was defined as seizure-free or a 50% or greater reduction in seizure frequency within a 1-year follow-up period.	Allele C is not associated with response to lamotrigine in people with Epilepsy as compared to allele T.	27610747	1448263559
HNF4A	rs3212183	CT	lamotrigine	metabolism/PK	no	Lamotrigine concentrations were measured as steady state in plasma in the early morning before breakfast after at least one month of continuous treatment with lamotrigine monotherapy.	Genotype CT is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.	27610747	1448263511
HNF4A	rs11086926	GG	metformin	efficacy	no	Subjects were at high risk of diabetes and were recruited from Diabetes Prevention Program (DPP) and were followed for a year. The authors measured changes in response to insulin at baseline and one year after treatment. Although the GG genotype was not associated with response to metformin, it was associated with changes in lifestyle as subjects with that genotype were less likely to develop diabetes compared with persons with the same genotype in the placebo (P=0.02) and metformin (P=0.02) groups.	Genotype GG is not associated with response to metformin as compared to genotypes GT + TT.	28453780	1448617616
HNF4A	rs3212185	CT	metformin	efficacy	no	Subjects were at high risk of diabetes and were recruited from Diabetes Prevention Program (DPP) and were followed for a year. The authors measured changes in response to insulin at baseline and one year after treatment. The C allele was not associated with response to Metformin (vs. Placebo) and after multiple testing corrections.	Genotype CT is not associated with response to metformin as compared to genotype CC.	28453780	1448617649
HNF4A	rs2071197	GG	oxcarbazepine	metabolism/PK	no		Genotype GG is not associated with concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.	28837897	1448998381
HNF4A	rs6031587	T	irinotecan	metabolism/PK	no		Allele T is not associated with metabolism of irinotecan in people with Colorectal Neoplasms as compared to allele C.	29706892	1449557367
HNF4A	rs3212207	C	rosuvastatin	metabolism/PK	yes		Allele C is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.	30100615	1449733134
HNF4A	rs1884613	CC	efavirenz	metabolism/PK	yes	ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily.	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CG + GG.	26774523	1447680404
HNF4A	rs2071197	AA + AG	lamotrigine	metabolism/PK	no	Lamotrigine concentrations were measured as steady state in plasma in the early morning before breakfast after at least one month of continuous treatment with lamotrigine monotherapy.	Genotypes AA + AG is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	27610747	1448263500
HNF4A	rs2071197	A	lamotrigine	efficacy	no	Efficacy was determined by monitoring the frequency of patients' epileptic seizures within one year. Each patient was evaluated at 4 weeks after treatment initiation and then at 3-month intervals thereafter. The difference in seizure frequency was based on the difference between the 3-month retrospective baseline frequency and the seizure frequency at 12-month visit, which was reported for the last 3 months prior to the last visit. Good efficacy was defined as seizure-free or a 50% or greater reduction in seizure frequency within a 1-year follow-up period.	Allele A is not associated with response to lamotrigine in people with Epilepsy as compared to allele G.	27610747	1448263553
HNF4A	rs2071197	A	oxcarbazepine	efficacy	no		Allele A is not associated with response to oxcarbazepine in people with Epilepsy as compared to allele G.	28837897	1448998411